Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. [electronic resource]
Producer: 20130417Description: 1517-26 p. digitalISSN:- 1525-1438
- Antineoplastic Agents -- administration & dosage
- Carcinoma, Endometrioid -- drug therapy
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Doxorubicin -- administration & dosage
- Drug Evaluation, Preclinical
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- Endometrial Neoplasms -- drug therapy
- Female
- Humans
- Mutation -- physiology
- Paclitaxel -- administration & dosage
- Pyrimidines -- administration & dosage
- Receptor, Fibroblast Growth Factor, Type 2 -- genetics
- Receptors, Fibroblast Growth Factor -- antagonists & inhibitors
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.